期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性硬化急性期与缓解期的治疗对策 被引量：4

原文传递
导出
摘要 多发性硬化（MS）是中枢神经系统（CNS）最常见的慢性炎性脱髓鞘疾病和CNS经典的自身免疫病,青壮年尤易罹患,病因及发病机制迄今未明.欧美国家MS发病率较高,估计全球有200万例患者,美国有35万～40万例,我国尚无统计数字.
作者 王维治
机构地区 哈尔滨医科大学附属第二医院神经内科
出处 《中华神经科杂志》 CAS CSCD 北大核心 2010年第7期522-524,共3页 Chinese Journal of Neurology
关键词 多发性硬化 缓解期 急性期 炎性脱髓鞘疾病 治疗 中枢神经系统 欧美国家 自身免疫病
分类号 R744.51 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献15

  • 1Goodin DS,Frohman EM,Garmany GP Jr,et al.Disease modifying therapies in multiple sclerosis:report of the Therapeuties and Technology Assessment Subeommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.Neurology,2002,58:169-178.
  • 2Fazekas F,Deisenhammer F,Strasser-Fuchs S,et al.Randomised placebo.controlled trial of monthly intravenous immunoglobulin in relapsing-remitting multiple sclerosis.Lancet,1977,349:589.
  • 3Keegan M,Pineda AA,McClelland RL,et al.Plasma exchange for severe attacks of CNS demyelination:predictors of response.Neurology,2002,58:143-146.
  • 4Cree BA.Multiple Bclerosis & demyelinating discases//Brust JC.Current diagnosis and treatment in neumlogy.London:McGrawHill,2007:255-261.
  • 5Anlar O.Treatment of multiple sclerosis.CNS Neurol Disord Drug Targets,2009,8:167-174.
  • 6Polman CH,O'Connor PW,Havrdova E,et al.A Randomized,placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med,2006,354:899-910.
  • 7Rudick RA,Stuart WH,Calabresi PA,et al.Natalimmab plus interferon beta-1a for relapsing multiple sclerosis.N Engl J Med,2006,354:911-923.
  • 8Bopper AH,Brown RH.Multiple sclerosis and allied demyelinative discases//Ropper AH.Brown RH.Adams and Victor's Principles of neurology.8th ed.Philadelphia:McGramHill,2005:787-788.
  • 9Noseworthy J,Confavreux C,Compston A.Treatment of acute relapse//McAlpine's Multiple Sclerosis.4th ed.New York:Elsevier,2005:683-699.
  • 10Hoganeamp WE,Noseworthy JH.Demyelinating disorders of the central nervous system//Goetz CG,Pappert EJ.Textbook of clinical neurology.Newborg:Saunders Company,1999:980-983.

二级参考文献13

  • 1王起,戚晓昆,刘建国,王巍,邱峰,段枫,熊斌.脱髓鞘假瘤35例的临床表现和影像及病理特点[J].中华神经科杂志,2007,40(7):456-459. 被引量：37
  • 2Cree BA.Multiple sclerosis and demyelinating diseases//Brust JC.Current diagnosis and treatment in neurology.New York:McGraw-Hill,2007:245-261.
  • 3Polman CH,Reingold SC,Edan G,et al.Diagnostic criteria for multiple sclerosis:2005 revisions to the "McDonald Criteria".Ann Neural,2005,58:840-846.
  • 4Tselis AC.Lisac RP.Other demyelinating diseases//Freedman MS.Advances in neurology.Vol.98.Multiple sclerosis and demyelinating diseases.Philadelphia:Lippincott Williams & Wilkins,2006:335-349.
  • 5MendezM,Pogacar S.Malignant monophasic multiple sclerosis or "Marburg's disease".Neurology,1988,38:1153-1155.
  • 6Chen CJ,Chu NS,Lu CS,et al.Serial magnetic resonance imaging in patients with Balo's concentric sclerosis:natural history of lesion development.Ann Neurol,1999,46:651-656.
  • 7Afifi A,Follett K,Greenlee J,et al.Optic neuritis:a novel presentation of Schilder's disease.J Child Neurol,2001,16:693-696.
  • 8Wingerchuk DM.Neuromyelitis optica//Freedman MS.Advances in neurology.Vol.98.Multiple sclerosis and demyelinating diseases.Philadelphia:Lippincott Williams & Wilkins,2006:319-333.
  • 9Wingerchuk DM,Hogancamp WF,O'Brien PC,et al.The clinical course of neuromyelitis optica (Devic's syndrome).Neurology,1999,53:1107-1114.
  • 10Lennon VA,Wingerchuk DM,Kryzer TJ,et al.A serum autoantibody marker of neuromyelitis optica:distinction from multiple sclerosis.Lancet,2004,364:2106-2112.

共引文献55

同被引文献40

  • 1Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology, 2005,64(7) : 1267-1269.
  • 2Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patientg Neurology, 2001, 56(10) : 1313-1318.
  • 3Ravikumar A, Arun P, Devi KV, et al. Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol, 2000,38 (5) : 438-446.
  • 4Sakai T, Inoue A, Koh CS, et al. A study of free radical defense and oxidative stress in the sera of patients with neuroimmunological disorders. Arerugi , 2000, 49( 1 ) : 12-18.
  • 5Haufschild T, Shaw SG, Kesselring J, et al. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neureophthalmol, 2001,21,(1):37-38.
  • 6Hirst C,Ingram G,Pearson O,et al.Contribution of relapses to disability in multiple sclerosis[J].J Neurol,2008,255(2):280-287.
  • 7Myhr KM,Mellgren SI.Corticosteroids in the treatment of multiple sclerosis[J].Acta Neurol Scand Suppl,2009,(189):73-80.
  • 8Goodin DS,Frohman EM,Garmany GP Jr,et al.Disease modifying therapies in multiple sclerosis:report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines[J].Neurology,2002,58(2):169-178.
  • 9Elovaara I,Apostolsk S,Van Doorn p,et al.EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological disease:EFNS task force on the use of intravenous immunoglobulin in treatment of neurological disease[J].Eur J Neurol,2008,15(9):893-908.
  • 10Weber MS,Hohlfeld R,Eamvil SS.Mechanism of actiom of glatiramer acetate in treatment of multiple sclerosis[J].Neurotherapeutics,2007,4(4):647-653.

引证文献4

二级引证文献7

中华神经科杂志
2010年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部